| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Bacampicillin targets penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. As a prodrug of ampicillin, it is hydrolyzed to ampicillin after absorption. Ampicillin binds to and inactivates PBPs, which are enzymes involved in the final stages of bacterial cell wall synthesis. This inactivation disrupts the cell wall, leading to bacterial cell lysis and death. Bacampicillin is a broad-spectrum antibiotic with bactericidal activity.
|
|---|---|
| ln Vitro |
In vitro, Bacampicillin is a prodrug that is converted to ampicillin, which exhibits bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. Its activity is typically measured using standard antimicrobial susceptibility tests, such as broth microdilution or disk diffusion assays, to determine the minimum inhibitory concentration (MIC) against various bacterial strains. These in vitro studies confirm the antibacterial activity of bacampicillin's active metabolite, ampicillin.
|
| ln Vivo |
In vivo, Bacampicillin is administered orally and is rapidly and almost completely absorbed. Peak absorption occurs 45 minutes to 1 hour after administration, which is faster than the peak absorption of ampicillin, which occurs at 2 hours. Bacampicillin is hydrolyzed to ampicillin in the body. It is used to treat infections caused by susceptible bacteria, such as respiratory tract infections, urinary tract infections, and skin and soft tissue infections.
|
| Enzyme Assay |
In vitro assays for Bacampicillin measure its antibacterial activity and its conversion to ampicillin. Antibacterial activity is assessed using standard broth microdilution or agar diffusion assays to determine the MIC against various bacterial strains. The hydrolysis of bacampicillin to ampicillin can be studied in vitro using esterase enzymes or serum, and the conversion can be monitored by HPLC. These assays confirm the compound's mechanism of action as a prodrug.
|
| Cell Assay |
In vitro cell-based assays for Bacampicillin are not typically performed, as the compound's mechanism of action is through the inhibition of bacterial cell wall synthesis. However, its effects on bacterial cells can be studied by treating bacterial cultures with Bacampicillin and assessing bacterial growth and viability. The compound's activity against various bacterial strains can be determined. These assays confirm the antibacterial activity of bacampicillin.
|
| Animal Protocol |
In vivo animal experiments for Bacampicillin are conducted in animal models of bacterial infections. In a typical study, Bacampicillin is administered orally to infected animals, and the reduction in bacterial load is measured. The compound's efficacy is compared to that of ampicillin or other antibiotics. Pharmacokinetic studies have also been conducted in ponies and horses. These studies confirm the in vivo efficacy and pharmacokinetics of Bacampicillin.
|
| ADME/Pharmacokinetics |
Bacampicillin hydrochloride has a molecular weight of 501.98 g/mol and a molecular formula of C21H28ClN3O7S. It is a solid compound. It is soluble in water and organic solvents. For storage, it is recommended to keep the powder at -20°C. Pharmacokinetic properties have been characterized. Bacampicillin is rapidly and almost completely absorbed after oral administration, with peak absorption occurring 45 minutes to 1 hour after administration. It is hydrolyzed to ampicillin in the body.
|
| Toxicity/Toxicokinetics |
Bacampicillin is an approved drug and its safety profile has been established. Common side effects include gastrointestinal disturbances, such as diarrhea, nausea, and vomiting. Allergic reactions, including rash and anaphylaxis, can occur in patients with penicillin hypersensitivity. As with all antibiotics, it should be used under medical supervision. For research use, standard laboratory safety precautions should be followed when handling Bacampicillin.
|
| References | |
| Additional Infomation |
Bacampicillin hydrochloride is the hydrochloride salt of Bacampicillin, which is a prodrug of ampicillin. Ampicillin is a broad-spectrum semi-synthetic β-lactam aminopenicillin antibiotic with bactericidal activity. In vivo, Bacampicillin is hydrolyzed by esterases to its active metabolite, ampicillin. Ampicillin binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of the bacterial cell wall. This disrupts bacterial cell wall synthesis, leading to decreased cell wall strength and ultimately cell lysis.
Bacampicillin hydrochloride is the hydrochloride salt of bacampicillin, a prodrug of ampicillin, a broad-spectrum, semisynthetic, beta-lactam aminopenicillin antibiotic. It is an improved oral bioavailability penicillin antibiotic. Bacampicillin is hydrolyzed in the body to its active metabolite, ampicillin. It is used to treat infections caused by susceptible bacteria. Bacampicillin is an approved drug and is also used as a research compound. |
| Exact Mass |
501.134
|
|---|---|
| Elemental Analysis |
C, 50.25; H, 5.62; Cl, 7.06; N, 8.37; O, 22.31; S, 6.39
|
| CAS # |
37661-08-8
|
| Related CAS # |
Bacampicillin;50972-17-3
|
| PubChem CID |
441398
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
695.4ºC at 760 mmHg
|
| Melting Point |
171-176° (dec)
|
| Flash Point |
374.3ºC
|
| LogP |
3.126
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
33
|
| Complexity |
756
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C.Cl
|
| InChi Key |
IWVTXAGTHUECPN-ANBBSHPLSA-N
|
| InChi Code |
InChI=1S/C21H27N3O7S.ClH/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12;/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25);1H/t11?,13-,14-,15+,18-;/m1./s1
|
| Chemical Name |
1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydrochloride
|
| Synonyms |
Bacampicillin HCl; Bacampicillin hydrochloride; 37661-08-8; bacampicillin HCl; Spectrobid; Ambaxin;Spectrobid; BAPC; Ambaxin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~249.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02099240 | TERMINATED | Drug: oral antibiotics Procedure: intravenous antibiotics |
Osteomyelitis | Julio Ramirez | 2014-03-06 | Early Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
